Sclerostin: Current Knowledge and Future Perspectives

go back to reference National Osteoporosis Foundation (2008) Facts on osteoporosis. http://www.nof.org/osteoporosis/diseasefacts.htm National Osteoporosis Foundation (2008) Facts on osteoporosis. http://​www.​nof.​org/​osteoporosis/​diseasefacts.​htm

go back to reference van Buchem FS, Hadders HN, Ubbens R (1955) An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol 44:109–120CrossRef van Buchem FS, Hadders HN, Ubbens R (1955) An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol 44:109–120CrossRef

go back to reference Hamersma H, Gardner J, Beighton P (2003) The natural history of sclerosteosis. Clin Genet 63:192–197CrossRefPubMed Hamersma H, Gardner J, Beighton P (2003) The natural history of sclerosteosis. Clin Genet 63:192–197CrossRefPubMed

go back to reference Beighton P, Barnard A, Hamersma H, van der Wouden A (1984) The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 25:175–181PubMedCrossRef Beighton P, Barnard A, Hamersma H, van der Wouden A (1984) The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 25:175–181PubMedCrossRef

go back to reference Beighton P (1988) Sclerosteosis. J Med Genet 25:200–203CrossRefPubMed Beighton P (1988) Sclerosteosis. J Med Genet 25:200–203CrossRefPubMed

go back to reference Gardner JC, van Bezooijen RL, Mervis B, Hamdy NAT, Löwik CWGM, Hamersma H, Beighton P, Papapoulos SE (2005) Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392–6395CrossRefPubMed Gardner JC, van Bezooijen RL, Mervis B, Hamdy NAT, Löwik CWGM, Hamersma H, Beighton P, Papapoulos SE (2005) Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392–6395CrossRefPubMed

go back to reference van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CWGM (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319–327CrossRefPubMed van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CWGM (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319–327CrossRefPubMed

go back to reference van Bezooijen RL, Papapoulos SE, Hamdy NAT, Lowik CWGM (2008) SOST/sclerostin; an osteocyte-derived inhibitor of bone formation that antagonizes canonical Wnt signaling. In: Raisz LG, Martin TJ, Bilezikian JP (eds) Principles of bone biology. Academic Press, New York, pp 139–152CrossRef van Bezooijen RL, Papapoulos SE, Hamdy NAT, Lowik CWGM (2008) SOST/sclerostin; an osteocyte-derived inhibitor of bone formation that antagonizes canonical Wnt signaling. In: Raisz LG, Martin TJ, Bilezikian JP (eds) Principles of bone biology. Academic Press, New York, pp 139–152CrossRef

go back to reference Hill SC, Stein SA, Dwyer A, Altman J, Dorwart R, Doppman J (1986) Cranial CT findings in sclerosteosis. AJNR Am J Neuroradiol 7:505–511PubMed Hill SC, Stein SA, Dwyer A, Altman J, Dorwart R, Doppman J (1986) Cranial CT findings in sclerosteosis. AJNR Am J Neuroradiol 7:505–511PubMed

go back to reference Stein SA, Witkop C, Hill SC, Fallon MD, Viernstein L, Gucer G, McKeever P, Long D, Altman J, Miller NR, Teitelbaum SL, Schlesinger S (1983) Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 33:267–277PubMed Stein SA, Witkop C, Hill SC, Fallon MD, Viernstein L, Gucer G, McKeever P, Long D, Altman J, Miller NR, Teitelbaum SL, Schlesinger S (1983) Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 33:267–277PubMed

go back to reference van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CWGM (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805–814CrossRefPubMed van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CWGM (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805–814CrossRefPubMed

go back to reference van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, van Hul W, Hamersma H, Dikkers FG, Hamdy NAT, Papapoulos SE, Löwik CWGM (2009) Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 88:569–574CrossRefPubMed van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, van Hul W, Hamersma H, Dikkers FG, Hamdy NAT, Papapoulos SE, Löwik CWGM (2009) Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 88:569–574CrossRefPubMed

go back to reference Epstein S, Hamersma H, Beighton P (1979) Endocrine function in sclerosteosis. S Afr Med J 55:1105–1110PubMed Epstein S, Hamersma H, Beighton P (1979) Endocrine function in sclerosteosis. S Afr Med J 55:1105–1110PubMed

go back to reference Beighton P, Durr L, Hamersma H (1976) The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med 84:393–397PubMed Beighton P, Durr L, Hamersma H (1976) The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med 84:393–397PubMed

go back to reference Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, van Hul W (2003) Patients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778–5783CrossRefPubMed Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, van Hul W (2003) Patients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778–5783CrossRefPubMed

go back to reference Balemans W, Ebeling M, Patel N, van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, van den Ende J, Willems P, Paes-Alves AF, Hill SC, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543CrossRefPubMed Balemans W, Ebeling M, Patel N, van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, van den Ende J, Willems P, Paes-Alves AF, Hill SC, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543CrossRefPubMed

go back to reference Brunkow ME, Gardner JC, van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589CrossRefPubMed Brunkow ME, Gardner JC, van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589CrossRefPubMed

go back to reference Balemans W, Cleiren E, Siebers U, Horst J, van Hul W (2005) A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36:943–947CrossRefPubMed Balemans W, Cleiren E, Siebers U, Horst J, van Hul W (2005) A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36:943–947CrossRefPubMed

go back to reference Kim CA, Honjo R, Bertola D, Albano L, Oliveira L, Jales S, Siqueira J, Castilho A, Balemans W, Piters E, Jennes K, van Hul W (2008) A known SOST gene mutation causes sclerosteosis in a familial and an isolated case from Brazilian origin. Genet Test 12:475–479CrossRefPubMed Kim CA, Honjo R, Bertola D, Albano L, Oliveira L, Jales S, Siqueira J, Castilho A, Balemans W, Piters E, Jennes K, van Hul W (2008) A known SOST gene mutation causes sclerosteosis in a familial and an isolated case from Brazilian origin. Genet Test 12:475–479CrossRefPubMed

go back to reference Balemans W, Patel N, Ebeling M, van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, van Hul W (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91–97CrossRefPubMed Balemans W, Patel N, Ebeling M, van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, van Hul W (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91–97CrossRefPubMed

go back to reference Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos SE, Hamersma H, Brunkow ME (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12–q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110:144–152CrossRefPubMed Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos SE, Hamersma H, Brunkow ME (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12–q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110:144–152CrossRefPubMed

go back to reference Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in van Buchem disease. Genome Res 15:928–935CrossRefPubMed Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in van Buchem disease. Genome Res 15:928–935CrossRefPubMed

go back to reference Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276CrossRefPubMed Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276CrossRefPubMed

go back to reference Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CWGM, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMed Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CWGM, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMed

go back to reference Ohyama Y, Nifuji A, Maeda Y, Amagasa T, Noda M (2004) Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 145:4685–4692CrossRefPubMed Ohyama Y, Nifuji A, Maeda Y, Amagasa T, Noda M (2004) Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 145:4685–4692CrossRefPubMed

go back to reference Balemans W, van Hul W (2002) Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250:231–250PubMed Balemans W, van Hul W (2002) Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250:231–250PubMed

go back to reference Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278:24113–24117CrossRefPubMed Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278:24113–24117CrossRefPubMed

go back to reference Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583CrossRefPubMed Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583CrossRefPubMed

go back to reference Pockwinse SM, Wilming LG, Conlon DM, Stein GS, Lian JB (1992) Expression of cell growth and bone specific genes at single cell resolution during development of bone tissue-like organization in primary osteoblast cultures. J Cell Biochem 49:310–323CrossRefPubMed Pockwinse SM, Wilming LG, Conlon DM, Stein GS, Lian JB (1992) Expression of cell growth and bone specific genes at single cell resolution during development of bone tissue-like organization in primary osteoblast cultures. J Cell Biochem 49:310–323CrossRefPubMed

go back to reference Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA (2004) Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35:448–454CrossRefPubMed Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA (2004) Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35:448–454CrossRefPubMed

go back to reference Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T (2008) Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 56:561–567CrossRefPubMed Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T (2008) Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 56:561–567CrossRefPubMed

go back to reference Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148–158CrossRefPubMed Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148–158CrossRefPubMed

go back to reference Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828–835CrossRefPubMed Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828–835CrossRefPubMed

go back to reference Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869CrossRefPubMed Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869CrossRefPubMed

go back to reference Avsian-Kretchmer O, Hsueh AJ (2004) Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol 18:1–12CrossRefPubMed Avsian-Kretchmer O, Hsueh AJ (2004) Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol 18:1–12CrossRefPubMed

go back to reference van Bezooijen RL, Papapoulos SE, Löwik CWGM (2005) Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest 28:15–17PubMed van Bezooijen RL, Papapoulos SE, Löwik CWGM (2005) Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest 28:15–17PubMed

go back to reference Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R (2006) Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738–1749CrossRefPubMed Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R (2006) Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738–1749CrossRefPubMed

go back to reference Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480CrossRefPubMed Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480CrossRefPubMed

go back to reference Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna KL, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513–1521CrossRefPubMed Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna KL, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513–1521CrossRefPubMed

go back to reference Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, van Eerdewegh P, Recker RR, Johnson ML (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11–19CrossRefPubMed Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, van Eerdewegh P, Recker RR, Johnson ML (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11–19CrossRefPubMed

go back to reference Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, de Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523CrossRefPubMed Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, de Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523CrossRefPubMed

go back to reference Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887CrossRefPubMed Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887CrossRefPubMed

go back to reference Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770–26775CrossRefPubMed Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770–26775CrossRefPubMed

go back to reference van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CWGM (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22:19–28CrossRefPubMed van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CWGM (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22:19–28CrossRefPubMed

go back to reference Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore AR, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284:10890–10900CrossRefPubMed Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore AR, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284:10890–10900CrossRefPubMed

go back to reference Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD (2009) NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun 380:160–165CrossRefPubMed Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD (2009) NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun 380:160–165CrossRefPubMed

go back to reference Hens JR, Wilson KM, Dann P, Chen X, Horowitz MC, Wysolmerski JJ (2005) TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 20:1103–1113CrossRefPubMed Hens JR, Wilson KM, Dann P, Chen X, Horowitz MC, Wysolmerski JJ (2005) TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 20:1103–1113CrossRefPubMed

go back to reference Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42:606–615CrossRefPubMed Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42:606–615CrossRefPubMed

go back to reference Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825–837CrossRefPubMed Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825–837CrossRefPubMed

go back to reference Knothe Tate ML, Adamson JR, Tami AE, Bauer TW (2004) The osteocyte. Int J Biochem Cell Biol 36:1–8CrossRefPubMed Knothe Tate ML, Adamson JR, Tami AE, Bauer TW (2004) The osteocyte. Int J Biochem Cell Biol 36:1–8CrossRefPubMed

go back to reference Han Y, Cowin SC, Schaffler MB, Weinbaum S (2004) Mechanotransduction and strain amplification in osteocyte cell processes. Proc Natl Acad Sci USA 101:16689–16694CrossRefPubMed Han Y, Cowin SC, Schaffler MB, Weinbaum S (2004) Mechanotransduction and strain amplification in osteocyte cell processes. Proc Natl Acad Sci USA 101:16689–16694CrossRefPubMed

go back to reference Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464–475CrossRefPubMed Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464–475CrossRefPubMed

go back to reference Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen DM, Zhao W, Li C, Kharode Y, Sauter L, Babij P, Brown EL, Hill AA, Akhter MP, Johnson ML, Recker RR, Komm BS, Bex FJ (2006) Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 281:31720–31728CrossRefPubMed Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen DM, Zhao W, Li C, Kharode Y, Sauter L, Babij P, Brown EL, Hill AA, Akhter MP, Johnson ML, Recker RR, Komm BS, Bex FJ (2006) Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 281:31720–31728CrossRefPubMed

go back to reference Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L (2009) Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24:1651–1661CrossRefPubMed Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L (2009) Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24:1651–1661CrossRefPubMed

go back to reference Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH (2006) The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698–23711CrossRefPubMed Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH (2006) The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698–23711CrossRefPubMed

go back to reference Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875CrossRefPubMed Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875CrossRefPubMed

go back to reference Moustafa A, Sugiyama T, Saxon LK, Zaman G, Sunters A, Armstrong VJ, Javaheri B, Lanyon LE, Price JS (2009) The mouse fibula as a suitable bone for the study of functional adaptation to mechanical loading. Bone 44:930–935CrossRefPubMed Moustafa A, Sugiyama T, Saxon LK, Zaman G, Sunters A, Armstrong VJ, Javaheri B, Lanyon LE, Price JS (2009) The mouse fibula as a suitable bone for the study of functional adaptation to mechanical loading. Bone 44:930–935CrossRefPubMed

go back to reference Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K (2009) Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 84:159–170CrossRefPubMed Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K (2009) Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 84:159–170CrossRefPubMed

go back to reference Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957–1967CrossRefPubMed Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957–1967CrossRefPubMed

go back to reference Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, di Vito M, Bonucci E (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261–269CrossRefPubMed Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, di Vito M, Bonucci E (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261–269CrossRefPubMed

go back to reference O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942CrossRefPubMed O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942CrossRefPubMed

go back to reference Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2009) Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178–189 Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2009) Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178–189

go back to reference Sevetson B, Taylor S, Pan Y (2004) Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem 279:13849–13858CrossRefPubMed Sevetson B, Taylor S, Pan Y (2004) Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem 279:13849–13858CrossRefPubMed

go back to reference Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE (2008) Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485–3497CrossRefPubMed Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE (2008) Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485–3497CrossRefPubMed

go back to reference Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135:3801–3811CrossRefPubMed Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135:3801–3811CrossRefPubMed

go back to reference Goldring SR, Goldring MB (2007) Eating bone or adding it: the Wnt pathway decides. Nat Med 13:133–134CrossRefPubMed Goldring SR, Goldring MB (2007) Eating bone or adding it: the Wnt pathway decides. Nat Med 13:133–134CrossRefPubMed

go back to reference Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588CrossRefPubMed Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588CrossRefPubMed

go back to reference Ominsky M, Stouch B, Doellgast G, Gong J, Cao J, Gao Y, Tipton B, Haldankar R, Winters A, Chen Q, Graham K, Zhou L, Hale M, Henry A, Lightwood D, Moore A, Popplewell A, Robinson M, Vlasseros F, Jolette J, Smith SY, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2006) Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. Read at the Annual Meeting of the American Society for Bone and Mineral Research, 2006 Sept 18, Philadelphia, PA Ominsky M, Stouch B, Doellgast G, Gong J, Cao J, Gao Y, Tipton B, Haldankar R, Winters A, Chen Q, Graham K, Zhou L, Hale M, Henry A, Lightwood D, Moore A, Popplewell A, Robinson M, Vlasseros F, Jolette J, Smith SY, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2006) Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. Read at the Annual Meeting of the American Society for Bone and Mineral Research, 2006 Sept 18, Philadelphia, PA

go back to reference Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK (2009) A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 24:1662–1671CrossRefPubMed Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK (2009) A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 24:1662–1671CrossRefPubMed

go back to reference Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris SE, Posvar E (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 21 Suppl 1:S37 Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris SE, Posvar E (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 21 Suppl 1:S37

go back to reference Whyte MP, Reinus WH, Mumm S (2004) High-bone-mass disease and LRP5. N Engl J Med 350:2096–2099CrossRefPubMed Whyte MP, Reinus WH, Mumm S (2004) High-bone-mass disease and LRP5. N Engl J Med 350:2096–2099CrossRefPubMed

go back to reference Rickels MR, Zhang X, Mumm S, Whyte MP (2005) Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J Bone Miner Res 20:878–885CrossRefPubMed Rickels MR, Zhang X, Mumm S, Whyte MP (2005) Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J Bone Miner Res 20:878–885CrossRefPubMed

go back to reference Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837–851CrossRefPubMed Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837–851CrossRefPubMed